CN114145354A - Formula milk powder containing breast milk oligosaccharide for preventing intestinal leakage and preparation method and application thereof - Google Patents

Formula milk powder containing breast milk oligosaccharide for preventing intestinal leakage and preparation method and application thereof Download PDF

Info

Publication number
CN114145354A
CN114145354A CN202111453114.8A CN202111453114A CN114145354A CN 114145354 A CN114145354 A CN 114145354A CN 202111453114 A CN202111453114 A CN 202111453114A CN 114145354 A CN114145354 A CN 114145354A
Authority
CN
China
Prior art keywords
formula
content
powder
intestinal
sialyllactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111453114.8A
Other languages
Chinese (zh)
Other versions
CN114145354B (en
Inventor
安晓楠
刘彪
孔小宇
王雯丹
吉塞拉·阿德里安娜·怀斯
司徒文佑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN202111453114.8A priority Critical patent/CN114145354B/en
Publication of CN114145354A publication Critical patent/CN114145354A/en
Application granted granted Critical
Publication of CN114145354B publication Critical patent/CN114145354B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/06—Mixtures of whey with milk products or milk components
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/10—Whey; Whey preparations containing inorganic additives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)

Abstract

The invention provides a formula milk powder containing breast milk oligosaccharide for preventing intestinal leakage and a preparation method and application thereof. Specifically, the invention provides formula milk powder, which contains breast milk oligosaccharides lactose-N-tetrasaccharide and 3 '-sialyllactose, wherein the mass ratio of lactose-N-tetrasaccharide to 3' -sialyllactose is (3-5): 1, and the total content of lacto-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g, based on the total mass of the formula. The invention also provides a preparation method of the formula milk powder and application of the formula milk powder in preventing intestinal leakage.

Description

Formula milk powder containing breast milk oligosaccharide for preventing intestinal leakage and preparation method and application thereof
Technical Field
The invention relates to formula milk powder containing breast milk oligosaccharide and a preparation method and application thereof, in particular to formula milk powder containing lactose-N-tetrasaccharide and 3' -sialyllactose and having the effect of preventing intestinal leakage, a preparation method and related application thereof, and belongs to the technical field of formula milk powder.
Background
Intestinal leakage (leaky gut), refers to the phenomenon in which increased intestinal permeability causes harmful substances in the intestine, such as bacteria and toxins, to pass through the intestinal mucosa into other tissues, organs and blood circulation in the human body. Gut permeability is associated with gut barrier function, and normal gut permeability depends on the integrity of the gut mucosal barrier. The intestinal mucosal barrier is a complex multi-layered system including physical, chemical, biological and immunological barriers. The interaction of these barriers allows the intestinal tract to maintain a permeability balance, preventing the loss of water and electrolytes and the entry of antigens and microorganisms into the body, while allowing molecular exchange between the body and the environment and the absorption of nutrients in the food.
The intestinal physical barrier, which is the first line of defense against the external environment, occupies a central position in the intestinal barrier structure and is composed of intestinal epithelial cells and intercellular junctions. Intestinal cell permeability is largely divided into transepithelial or transcellular permeability and paracellular permeability. Cell bypass permeability is dependent on transport through interstitial spaces between cells. The intercellular junction includes tight junction, adhesion junction, desmosomes, etc., and most importantly, the tight junction is located at the apical end of the intestinal epithelial cell outer membrane and has a long and narrow band-like structure to block the intercellular space, thereby preventing macromolecular substances such as bacteria and toxins, etc. in the intestinal lumen from entering the blood circulation through the intercellular space. The intercellular tight junction structure has high dynamic stability, and its permeability determines the barrier function of the whole intestinal epithelial cell, and is regulated by intracellular and extracellular signals, and can be affected by diet, diseases, stress, etc.
The intestinal chemical barrier is mainly composed of the mucus layer, which can alter the sites of intestinal microorganisms, preventing them from coming into direct contact with the host intestinal tissue cells. In addition, some substances produced in the intestinal tract, such as bile salts, mucopolysaccharides, lysozyme and glycoproteins, can also play a role in chemical barriers.
The intestinal biological barrier is a micro-ecosystem with dynamic stability formed by intestinal symbiotic bacteria and a host, the intestinal symbiotic bacteria are attached to a mucous membrane layer on the surface of the intestinal tract of the host to form a microbial barrier formed by bacteria, and the intestinal biological barrier inhibits the colonization and the propagation of pathogenic bacteria through mechanisms such as competitive adhesion.
In the intestinal immunity barrier, intestinal tract-related lymphoid tissues play a role in juggling, wherein lymphocytes, macrophages and the like play a role in resisting pathogen invasion, and in intestinal tract immunity effector molecules, secretory immunoglobulin A (sIgA) plays a key role, is produced in an intestinal tract lamina propria and is secreted into an intestinal cavity after being processed by intestinal tract epithelial cells, can block adhesion of antigens such as bacteria, toxins and viruses on mucous membranes, and plays a role in clearing the antigens.
Intestinal leakage due to dysfunction of the intestinal barrier is a major potential cause of many health problems, including irritable bowel syndrome, headache, weight gain, hashimoto's thyroiditis, anxiety, depression, autoimmune diseases and allergies, among others. In particular, microbial toxins produced by the metabolism of the intestinal flora or other toxins entering with food enter the blood circulation through the intestinal wall with increased permeability ("intestinal leakage"), and cause various autoimmune symptoms by stimulating the autoimmune system or poisoning internal organs, thereby causing various diseases.
Compared with the infants fed by breast milk, the infants not fed by breast milk have poor intestinal development and are easy to have intestinal leakage.
Therefore, there is a need for a solution that can prevent the occurrence of intestinal leakage to promote intestinal health.
Disclosure of Invention
One object of the present invention is to provide a formula milk powder capable of preventing intestinal leakage.
The invention also aims to provide a preparation method of the formula milk powder.
The invention also aims to provide application of the formula milk powder.
The inventor finds in experimental research that breast milk oligosaccharide lacto-N-tetraose (LNT) and 3 ' -sialyllactose (3 ' -sialyllactose, 3 ' -SL or 3SL) can be combined according to a specific ratio to prevent or improve intestinal leakage or intestinal barrier injury, and is favorable for improving intercellular intestinal permeability and intestinal barrier, improving intercellular gaps, and particularly favorable for maintaining infant intestinal health. Therefore, the lactose-N-tetrasaccharide and the 3' -sialyllactose are added into the milk powder, and the formula milk powder capable of preventing intestinal leakage and promoting intestinal health is provided.
lacto-N-tetraose, a hexasaccharide structure formed by lactose and tetraose, is a representative substance of oligosaccharides having a core sugar chain as a basic structure and not containing fucosyl or sialyl groups, which is generally commercially available through a microbial fermentation process and has the same structure as lacto-N-tetraose found in human milk.
3' -sialyllactose is a trisaccharide structure formed by sialic acid and lactose, and is a representative substance of sialyl oligosaccharides. The commercial products of 3 '-sialyllactose in the prior art are mostly prepared by microbial fermentation methods and have the same structure as 3' -sialyllactose found in human milk.
Specifically, in one aspect, the invention provides a formula milk powder, which contains breast milk oligosaccharides lactose-N-tetrasaccharide and 3 '-sialyllactose, wherein the mass ratio of lactose-N-tetrasaccharide to 3' -sialyllactose is (3-5): 1, and the total content of lacto-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g, based on the total mass of the formula.
According to a particular embodiment of the invention, the formula of the invention is a non-infant milk powder or an infant formula. Wherein the non-infant milk powder can be milk powder for children or milk powder for adults (including the middle-aged and the elderly).
According to a specific embodiment of the invention, in the formula milk powder, the total protein content of the formula milk powder is 10-20 g/100g based on the total mass of the formula milk powder; the fat content is 15-30 g/100 g; the carbohydrate content is 50-70 g/100 g.
According to a specific embodiment of the invention, the formula milk powder further contains linoleic acid and alpha-linolenic acid, wherein the content of the linoleic acid is 2700-4500 mg/100g and the content of the alpha-linolenic acid is 270-450 mg/100g based on the total mass of the formula milk powder.
According to a specific embodiment of the invention, the ratio by mass of lacto-N-tetraose to 3' -sialyllactose in the formula of the invention is 4: 1.
according to a particular embodiment of the invention, the total content of lacto-N-tetraose and 3' -sialyllactose in the formula of the present invention is 18-2841mg/100g, based on the total mass of the formula.
According to a particular embodiment of the invention, the total content of lacto-N-tetraose in the formula of the milk powder of the invention is not less than 14.2mg/100g, preferably 14.2-2273.0mg/100g, based on the total mass of the formula. In some embodiments of the present invention, the total content of lacto-N-tetraose in the milk formula of the present invention is 70.9-1515.3mg/100g powder, preferably 70.9-757.7mg/100g, based on the total mass of the milk formula.
In addition, the amount of 3' -sialyllactose used in the formula of the present invention is used with reference to the aforementioned proportions, unless otherwise noted.
In some specific embodiments, the total content of lacto-N-tetraose and 3' -sialyllactose in the milk formula of the invention may be 2000-3000mg/100 g. In some specific embodiments, the total content of lacto-N-tetraose and 3' -sialyllactose in the milk powder formulations of the invention may be 500-1800mg/100g powder. In some specific embodiments, the total content of lacto-N-tetraose and 3' -sialyllactose in the formula of the present invention may be from 18 to 300mg per 100g of powder.
In some specific embodiments of the invention, the formula powder of the invention is a formula powder for infants of 0-6 months, wherein the total protein content is 10-15 g/100g, the fat content is 23-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-60 g/100g based on the total mass of the formula powder. In some more specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the formula may be 3000mg/100g powder, preferably 2200-2841mg/100g powder.
In some specific embodiments of the invention, the formula powder of the invention is a formula powder for infants with 6-12 months old, wherein the total protein content is 10-20 g/100g, the fat content is 20-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-65 g/100g based on the total mass of the formula powder. In some more specific embodiments, the total content of lactose-N-tetraose and 3' -sialyllactose in the milk formula may be in the range of 500-1800mg/100g powder, such as 800-1500mg/100g powder, preferably 900-1200mg/100g powder.
In some specific embodiments of the invention, the formula powder is a formula powder for infants of 12-36 months, wherein the total protein content is 10-20 g/100g, the fat content is 15-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-70 g/100g, based on the total mass of the formula powder. In some more specific embodiments, the total content of lacto-N-tetraose and 3' -sialyllactose in the formula may be from 18 to 300mg per 100g of powder, for example from 50 to 200mg per 100g of powder, preferably from 80 to 150mg per 100g of powder.
According to a specific embodiment of the present invention, the raw materials for providing total protein in the formula of the present invention comprise: raw milk (cow/sheep), whole milk powder (cow/sheep), skimmed milk powder (cow/sheep), whey protein powder (cow/sheep), desalted whey powder (cow/sheep), and one or more of beta-casein. Specifically, the formula milk powder comprises the following raw materials in parts by weight based on 1000 parts by weight: 0-3500 parts of raw milk (cow/sheep), 0-260 parts of whole milk powder (cow/sheep), 0-120 parts of whey protein powder (cow/sheep), 0-400 parts of skimmed milk powder (cow/sheep), and/or 0-600 parts of desalted whey powder (cow/sheep), and 0-40 parts of beta-casein.
According to a specific embodiment of the present invention, in the formula of the present invention, the raw material for providing fat comprises one or more of the following raw materials in parts by weight: 0-50 parts of corn oil, 0-65 parts of soybean oil, 0-100 parts of sunflower seed oil, 0-240 parts of 1, 3-dioleoyl-2-palmitic triglyceride, 0-30 parts of coconut oil, 0-85 parts of low erucic acid rapeseed oil and 0-20 parts of linseed oil.
According to a specific embodiment of the present invention, the raw material for providing breast milk oligosaccharide in the formula of the present invention is commercially available food grade breast milk oligosaccharide raw material.
According to a specific embodiment of the present invention, the raw materials for providing carbohydrates in the formula of the present invention comprise: 0-500 parts of lactose and/or the protein raw material containing lactose.
According to a particular embodiment of the invention, the formula of the invention, in particular of infant formula, may comprise, in addition to the above-mentioned components, the usual components of formula, for example, in the case of infant formula, one or more of nutrients, dietary fibres, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin. Preferably comprises a compound nutrient bag. In some preferred embodiments, the infant formula includes 0-20 parts of nutrients including vitamins and minerals, or further optionally one or more of dietary fiber (fructooligosaccharides, galactooligosaccharides, polyfructose, etc.), inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin. The compound nutrient mainly comprises: compounding vitamins: vitamin A, vitamin D, vitamin E, and vitamin K1Vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, choline and organismA peptide; compounding minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium and derivatives thereof. The source, content and usage amount of the vitamins and minerals should meet the national standard and relevant regulations of milk powder or infant formula food.
On the other hand, the invention also provides a method for preparing the formula powder, which adopts a wet method or a dry method production process to mix breast milk oligosaccharides lactose-N-tetrasaccharide and 3' -sialyllactose with other raw materials in the formula powder to prepare the formula powder. The preparation process mainly comprises the following steps: preparing materials, homogenizing, concentrating, sterilizing, spray drying, and dry mixing to obtain the final product. In the present invention, the lacto-N-tetraose and the 3' -sialyllactose may be mixed together during compounding, or may be added during post-mixing or dry-blending. The specific method conditions can be carried out according to the conventional method in the field of formula milk powder production.
On the other hand, the invention also provides the application of the formula milk powder as a food with the function of preventing intestinal leakage. In other words, the present invention provides the use of a breast milk oligosaccharide composition comprising lacto-N-tetraose and 3' -sialyllactose in the preparation of a food product (formula) having an intestinal leakage prevention effect.
According to a particular embodiment of the invention, said prevention of intestinal leakage comprises improving intercellular intestinal permeability and/or intestinal barrier.
According to a particular embodiment of the invention, said prevention of intestinal leakage comprises reducing intercellular spaces.
In summary, the present invention provides a milk formula containing lacto-N-tetraose and 3' -sialyllactose. The formula milk powder can be used for preventing or improving intestinal leakage or intestinal barrier injury, is favorable for improving intercellular intestinal permeability and intestinal barrier, improves intercellular gaps, and is particularly favorable for maintaining infant intestinal health.
Drawings
Fig. 1 shows the effect of breast milk oligosaccharides on the molecular transport of FD 4.
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description of the technical aspects of the present invention with reference to specific examples, which are intended to illustrate the present invention and not to limit the scope of the present invention.
Unless specifically defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the relevant art.
In the examples, the raw materials of lacto-N-tetraose and 3 '-sialyllactose are from the supplier Jennewein, and the content of lacto-N-tetraose and 3' -sialyllactose is determined by the conventional method in the field. The operating conditions not specified in detail in the examples were carried out according to the usual procedures in the art.
Example 1
The embodiment provides a powdery infant formula with the age of 0-6 months, wherein the total protein content of the powdery infant formula is 10.5g/100g of powder, and the fat content of the powdery infant formula is 27.9g/100g of powder; the carbohydrate content was 53.5g/100g powder; the content of the breast milk oligosaccharide composition is 2.8g/100g powder.
In the embodiment, the infant formula powder is prepared by compounding the following raw materials in parts by weight (1000 parts by weight):
1300 parts of raw milk, 500 parts of desalted whey powder, 220 parts of mixed vegetable oil (containing OPO), 90 parts of lactose, 15 parts of skimmed milk powder, 5 parts of whey protein powder and 31 parts of breast milk oligosaccharide LNT and 3 '-SL composition, wherein the mass ratio of LNT to 3' -SL is about 3:1, 2.5 parts of compound vitamin and 8 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, and dry mixing with the breast milk oligosaccharide composition to obtain the final product.
Example 2
The embodiment provides a powdery formula food for 6-12 months old older babies, wherein the total protein content of the powdery formula food is 12.0g/100g of the powder, and the fat content of the powdery formula food is 23.3g/100g of the powder; the carbohydrate content was 54.6g/100g powder; the content of the breast milk oligosaccharide composition is 0.9g/100g powder.
In the embodiment, the infant formula powder is prepared by compounding the following raw materials in parts by weight (1000 parts by weight):
280 parts of desalted whey powder (sourced from goat milk), 220 parts of full-cream goat milk powder, 155 parts of mixed vegetable oil (containing OPO structural fat), 100 parts of lactose, 210 parts of lactose, 40 parts of whey protein powder (sourced from goat milk), 10 parts of breast milk oligosaccharide LNT and 3 '-SL composition, wherein the mass ratio of LNT to 3' -SL is about 4:1, 3.5 parts of compound vitamin and 15 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, and dry mixing with the breast milk oligosaccharide composition to obtain the final product.
Example 3
The embodiment provides powdery formula goat milk powder for infants of 12-36 months old, wherein the total protein content of the powdery formula food is 13.0g/100g of the powder, and the fat content of the powdery formula food is 23.1g/100g of the powder; the carbohydrate content was 57.5g/100g powder; the content of the breast milk oligosaccharide composition is 0.1g/100g powder.
The embodiment prepares the infant formula powder by compounding the following raw materials in parts by weight (1000 parts by weight):
1000 parts of raw milk, 225 parts of desalted whey powder, 225 parts of skimmed milk powder, 240 parts of lactose, 180 parts of mixed vegetable oil (containing OPO structural fat), 5 parts of whey protein powder and 1.1 parts of breast milk oligosaccharide LNT and 3 '-SL composition, wherein the mass ratio of LNT to 3' -SL is about 5:1, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, and dry mixing with the breast milk oligosaccharide composition to obtain the final product.
Experiment for improving intestinal leakage by breast milk oligosaccharide
1. Experiment for improving cell bypass permeability
The experiment inspects the influence of different HMOs and compositions thereof on the epithelial function of the small intestine under normal conditions, and shows that the intestinal permeability and the intestinal barrier (cell bypass permeability) between cells are improved through indexes such as the intestinal barrier and FD4 (fluorescein isothiocyanate dextran; FITC labeled dextran) molecular transport condition and the like.
Normal (non-invasive) condition
Caco-2 cells were cultured in DMEM medium in a transwell system for 21 days to simulate the small intestine epithelial cell layer. The test HMO or HMO composition (final concentration 0.1mg/mL in the culture system) was added and cultured for 24 hours, and then FD4 molecule (final surface concentration 250ug/mL) was added and the culture was continued. FD4 molecular transport was measured as three biological replicates at 24 hours of continued culture. A DMEM medium control was also set without any HMO or HMO composition tested.
Data analysis
The permeability data of FD4 for molecular transport was statistically analyzed using two-tailed paired T-test. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.
Results of the experiment
The results are shown in FIG. 1. For most HMO and HMO composition test groups, FD4 transport was closer to the DMEM control. The mass ratio of the invention is 4: the HMO composition of the LNT and the 3 '-SL of the invention 1 obviously reduces the transport of FD4 molecules (P <0.05), and shows that the composition of the LNT and the 3' -SL of the invention can improve the intercellular intestinal permeability (reduce the intercellular intestinal permeability), improve the intestinal barrier effect, and the analysis reason is mainly to reduce the intercellular gap and improve the intercellular tightness, so that the tightness of the paracellular transport pathway is increased, and the intestinal leakage can be effectively reduced.
TcDA invasion assay
The experiment examines the influence of HMO compositions (the mass ratio of LNT to 3' -SL is 2: 1 and 4:1 respectively) with different proportions on the small intestine epithelial function under the condition of invasion by microbial toxin Clostridium difficile toxin A (TcDA), and the expression of the TEER index of transmembrane resistance is determined through a TcDA invasion experiment.
Caco-2 cells were cultured in DMEM medium in a transwell system for 21 days to simulate the small intestine epithelial cell layer. The test HMO composition (final concentration in the culture system 0.1mg/mL) was added and incubated for 24 hours, followed by addition of TcDA (final surface concentration of 200ug/mL) and continued incubation. Transmembrane resistance TEER was measured at 0, 3 hours of continued culture with TcDA added, and three times were measured as biological replicates. A DMEM medium control was also set without any HMO or HMO composition tested.
Data analysis
For the data of transmembrane resistance TEER, statistical analysis was performed using Tukey's multiple comparison test. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.
Results of the experiment
Table 1 shows the effect of LNT and 3' -SL combination on transmembrane resistance as measured after three hours of incubation with toxin A.
TABLE 1
Figure BDA0003385685120000091
From the results of intestinal barrier test for three hours, it can be seen that the mass ratio of 2: the LNT + 3' -SL composition of 1 significantly reduced transmembrane resistance compared to the control, whereas the mass ratio of the invention was 4: the LNT +3 '-SL composition of 1 did not significantly reduce transmembrane resistance, reflecting the tendency of the present invention to be synergistic between LNT and 3' -SL compositions in a specific ratio range.

Claims (10)

1. The formula milk powder contains breast milk oligosaccharide lactose-N-tetrasaccharide and 3 '-sialyllactose, wherein the mass ratio of the lactose-N-tetrasaccharide to the 3' -sialyllactose is (3-5): 1, and the total content of lacto-N-tetraose and 3' -sialyllactose in the formula is 18-3000mg/100g, based on the total mass of the formula.
2. The formula of claim 1, wherein the total protein content is 10-20 g/100g, and the fat content is 15-30 g/100 g; the carbohydrate content is 50-70 g/100 g;
preferably, the formula milk powder also contains linoleic acid and alpha-linolenic acid, and based on the total mass of the formula milk powder, the content of the linoleic acid is 2700-4500 mg/100g, and the content of the alpha-linolenic acid is 270-450 mg/100 g.
3. The formula of claim 1, wherein the formula is for infants of 0-6 months old, and the total protein content is 10-15 g/100g, the fat content is 23-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-60 g/100 g.
4. The formula of claim 1, wherein the formula is for infants with 6-12 months old, and the total weight of the formula is 10-20 g/100g of total protein, 20-30 g/100g of fat, 2700-4500 mg/100g of linoleic acid, 270-450 mg/100g of alpha-linolenic acid and 50-65 g/100g of carbohydrate.
5. The formula of claim 1, wherein the formula is for infants of 12-36 months, and the total protein content is 10-20 g/100g, the fat content is 15-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-70 g/100 g.
6. Formula according to any one of claims 1 to 5, wherein the lacto-N-tetraose is used in the formula in an amount of 70.9 to 1515.3mg/100g, preferably 70.9 to 757.7mg/100g, based on the total mass of the formula.
7. The formula of any one of claims 1 to 6, wherein the formula further comprises one or more of nutrients, dietary fibers, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, and lactoferrin.
8. The formula of claim 1, wherein the formula is for preventing intestinal leakage, wherein the prevention of intestinal leakage comprises improving intercellular intestinal permeability and/or intestinal barrier, and/or reducing intercellular gaps.
9. A process for the preparation of a milk formula according to any one of claims 1 to 8, which comprises:
the formula powder is prepared by mixing breast milk oligosaccharide lactose-N-tetrasaccharide and 3' -sialyllactose with other raw materials in the formula milk powder by a wet or dry production process.
10. Use of the formula of any one of claims 1 to 8 as a food with the effect of preventing intestinal leakage.
CN202111453114.8A 2021-11-30 2021-11-30 Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof Active CN114145354B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111453114.8A CN114145354B (en) 2021-11-30 2021-11-30 Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111453114.8A CN114145354B (en) 2021-11-30 2021-11-30 Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114145354A true CN114145354A (en) 2022-03-08
CN114145354B CN114145354B (en) 2023-08-22

Family

ID=80455547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111453114.8A Active CN114145354B (en) 2021-11-30 2021-11-30 Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114145354B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501638A (en) * 2010-12-31 2014-01-08 雅培制药有限公司 Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN105532883A (en) * 2015-12-21 2016-05-04 海普诺凯营养品有限公司 Formula goat milk powder for infants and young children and preparation method thereof
CN107106584A (en) * 2014-12-08 2017-08-29 格礼卡姆股份公司 Synthetic composition for treating dysbolism
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
CN110506793A (en) * 2019-09-23 2019-11-29 石家庄君乐宝乳业有限公司 Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof
CN112514997A (en) * 2020-11-30 2021-03-19 内蒙古伊利实业集团股份有限公司 Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof
CN112535218A (en) * 2020-12-08 2021-03-23 石家庄君乐宝乳业有限公司 Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof
CN112868800A (en) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof
CN113163833A (en) * 2018-12-21 2021-07-23 雀巢产品有限公司 Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501638A (en) * 2010-12-31 2014-01-08 雅培制药有限公司 Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN107106584A (en) * 2014-12-08 2017-08-29 格礼卡姆股份公司 Synthetic composition for treating dysbolism
CN105532883A (en) * 2015-12-21 2016-05-04 海普诺凯营养品有限公司 Formula goat milk powder for infants and young children and preparation method thereof
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
CN113163833A (en) * 2018-12-21 2021-07-23 雀巢产品有限公司 Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function
CN110506793A (en) * 2019-09-23 2019-11-29 石家庄君乐宝乳业有限公司 Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof
CN112868800A (en) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof
CN112514997A (en) * 2020-11-30 2021-03-19 内蒙古伊利实业集团股份有限公司 Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof
CN112535218A (en) * 2020-12-08 2021-03-23 石家庄君乐宝乳业有限公司 Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof

Also Published As

Publication number Publication date
CN114145354B (en) 2023-08-22

Similar Documents

Publication Publication Date Title
RU2607457C2 (en) Milk oligosaccharide-galactooligosaccharide composition for infant formula, containing soluble oligosaccharide fraction present in milk, and having low level of monosaccharides, and process to produce composition
ES2342625T5 (en) Oligosaccharide mixture
TWI391100B (en) Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
CZ2003535A3 (en) Foodstuff preparation
WO2016029113A1 (en) Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
Seki et al. Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men
CN110996686A (en) Nutritional composition containing human milk oligosaccharides and uses thereof
CN114128767B (en) Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides
Angus et al. Prebiotic ingredients with emphasis on galacto‐oligosaccharides and fructo‐oligosaccharides
CN114145353A (en) Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN114208893A (en) Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN116076728B (en) Composition for promoting growth of bifidobacteria
CN114145354B (en) Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof
CN114271340A (en) Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof
CN104824511A (en) Prebiotics composition
WO2022266058A1 (en) Methods and compositions for treating gas
CN114451453B (en) Breast milk oligosaccharide composition for preventing intestinal leakage and application thereof
JPH1029945A (en) Enteric metabolism-improving agent
Dong et al. Research progress of probiotics and prebiotics in ajuvant therapy for diseases and prospect of their application in functional foods
CN114452295A (en) Use of lacto-N-tetraose for preventing intestinal leakage
CN112384079A (en) Nutritional composition for treating diarrhea, preparation and treatment method thereof
Belchik Evaluation of GNU100 on fecal characteristics, microbiota, and bile acid concentrations of healthy adult dogs treated with antibiotics
US20220400729A1 (en) Synergistic combination of butyric-acid-producing prebiotics and probiotics
CN117481201A (en) Formula milk powder for promoting brain development and preparation method and application thereof
Durham Sources and Strategies for Improving the Isolation of Oligosaccharides from Milk and Dairy Streams

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant